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We previously developed a lymphoblastoid cell line (LCL) model of mitochondrial dysfunction 
in autism spectrum disorder (ASD); some individuals with ASD showed mitochondrial 
dysfunction (AD-A) while other individuals (AD-N) demonstrated mitochondrial respiration 
similar to controls (CNT). To test the hypothesis that mitochondrial dysfunction could be 
a consequence of environmental exposures through chronic elevations in reactive oxygen 
species (ROS), we exposed LCLs to prolonged ROS. We also examined expression 
of metabolic regulatory genes and the modulating effect of the mechanistic target of 
rapamycin (mTOR) pathway. Prolonged ROS exposure induced or worsened mitochondrial 
dysfunction in all LCL groups. Expression of genes associated with ROS protection was 
elevated in both AD-N and AD-A LCLs, but mitochondrial fission/fusion and mitoplasticity 
gene expression was only increased in AD-N LCLs. Partial least squares discriminant 
analysis showed that mTOR, UCP2 (uncoupling protein 2), SIRT1 (sirtuin 1), and MFN2 
(mitofusin-2) gene expression differentiated LCL groups. Low-dose rapamycin (0.1 nM) 
normalized respiration with the magnitude of this normalization greater for AD-A LCLs, 
suggesting that the mammalian target of rapamycin complex 1 (mTORC1) pathway may 
have a different dynamic range for regulating mitochondrial activity in individuals with ASD 
with and without mitochondrial dysfunction, potentially related to S6K1 (S6 kinase beta-1) 
regulation. Understanding pathways that underlie mitochondrial dysfunction in ASD may 
lead to novel treatments.
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INTRODUCTION
Mitochondria are involved in many essential cellular functions; besides production of adenosine 
triphosphate (ATP), mitochondria are essential for calcium buffering, redox regulation, apoptosis, 
and inflammation. Classic mitochondrial diseases are rare, but novel forms of mitochondrial 
dysfunction are believed to be associated with more common diseases, particularly those where the 
environment contributes to the etiology. Mitochondrial dysfunction is documented in psychiatric 
diseases (1–4), neurodegenerative disorders (5), persistent systemic inflammation (6), cardiac 
disease (7), cancer (8), and diabetes (9). Mitochondrial dysfunction is also closely associated with 
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neurodevelopmental disorders, particularly autism spectrum 
disorder (ASD) (10, 11) and genetic syndromes closely associated 
with ASD including mechanistic target of rapamycin (mTOR) 
(12–15); phosphatase and tensin homolog (PTEN) (16) and 
WDR45 (17) mutations; Rett (18–20), Phelan–McDermid (21), 
Angelman (22), and Down (23, 24) syndromes; as well as 15q11-
q13 duplication (25, 26) and septo-optic dysplasia (27).
Mitochondrial dysfunction in ASD is unique. First, 
the great majority (~75%) of those with both ASD and 
mitochondrial disease do not show mitochondrial or nuclear 
genetic abnormalities, suggesting that the changes in 
mitochondrial function are either secondary to alterations 
in nonmitochondrial metabolic or regulatory pathways and/
or due to changes in nonmitochondrial genes or epigenetic 
changes (11). Second, unlike classic mitochondrial disease, 
where mitochondrial activity is depressed, electron transport 
chain (ETC) activity in individuals with ASD has been 
reported to be elevated significantly above normal in muscle 
(28, 29), skin (30), gut mucosa (31), buccal epithelium (32–
34), and brain (35).
In a series of studies, the authors have described and validated 
a lymphoblastoid cell line (LCL) model of mitochondrial 
dysfunction in samples obtained from individuals with ASD 
(36–42). In this model, about one-third of individuals with 
ASD (called AD-A) have LCLs with respiratory rates twice that 
of LCLs from control (CNT) individuals, while the remainder 
of the individuals with ASD (called AD-N) have LCLs with 
respiratory rates equivalent to LCLs from CNT individuals. 
Using the Mitochondrial Oxidative Stress Test (MOST) (43), we 
systematically increased reactive oxygen species (ROS) in vitro to 
demonstrate that AD-A LCLs are sensitive to physiological stress 
as they consistently show a depletion in reserve capacity (RC) as 
ROS is increased (36–42). In addition, we have demonstrated that 
mitochondrial respiration of AD-A LCLs responds differently 
to environmental toxicants (38, 40) and enteric short-chain 
fatty acids (39, 42) as compared to mitochondrial function in 
AD-N and CNT LCLs. In addition, we have linked this atypical 
mitochondrial function seen in AD-A LCLs to ASD behaviors; 
indeed, higher respiratory rates in the ASD LCLs were found to 
be associated with more severe repetitive behaviors measured on 
the gold-standard diagnostic tool for ASD, the Autism Diagnostic 
Observation Schedule (ADOS) (41).
The reason for the abnormal mitochondrial function in the 
AD-A LCLs is not obvious; we previously hypothesized that this 
elevation in mitochondrial respiration was an adaptive response 
that developed as a consequence of previous exposure(s) to 
chronic extrinsic and/or intrinsic stressors (37), a hypothesis 
that this paper is designed to test. Since many environmental 
stressors may have their biological effect through increases 
in ROS (21, 44–46) and since ROS is elevated in many ASD-
derived tissues (45), including LCLs (37) and brain (47, 48), 
we hypothesized that prolonged environmental exposures, 
potentially through prolonged exposure to ROS, would alter 
long-term mitochondrial function by increasing respiratory 
rates. Since this hypothesis has never been tested directly, we 
will test this hypothesis in this paper by exposing ASD and CNT 
LCLs to prolonged ROS.
Thus, in this study, we determine whether prolonged exposure to 
ROS will increase mitochondrial respiratory rates in our LCL model 
so that LCLs with normal mitochondrial respiration (i.e., AD-N, 
CNT) will demonstrate increases in mitochondrial respiration 
and LCLs with increased respiration (i.e., AD-A) will further 
demonstrate increases in mitochondrial respiration. Showing that 
such a change can be induced would support the hypothesis that 
this change in mitochondrial respiration is inducible.
We also examined changes in molecular pathways associated 
with mitochondrial dysfunction by measuring the expression of 
genes, including those involved in regulating redox metabolism 
(uncoupling protein 2, UCP2; mitochondrial superoxide 
dismutase 2, SOD2) (49–51), mitochondrial response to stress 
(sirtuin 1, SIRT1; sirtuin 3, SIRT3; hypoxia-inducible factor 
1-alpha, HIF1α; peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha, PGC1α) (52–54), mitophagy (PTEN-
induced putative kinase 1; PINK1), mitochondrial fusion 
(mitofusin-2, MFN2), mitochondrial fission (dynamin-1-like 
protein, DRP1), and those that can modulate cellular metabolism 
(AMP-activated protein kinase, AMPK; RAC-alpha serine/
threonine-protein kinase, AKT1) and are associated with ASD 
(PTEN; mTOR) (55). We examined both the average expression 
across groups and the relationship between expressions of genes 
in various pathways.
Lastly, we examined the relationship of bioenergetic 
abnormalities found in ASD LCLs to the mTOR pathway 
for several reasons. First, abnormalities in mTOR complex 1 
(mTORC1) signaling occurs in approximately 25% of individuals 
with nonsyndromic autism (56), which is a similar proportion 
of ASD LCLs with atypical bioenergetics (36, 37) (i.e., AD-A) 
in our model. Second, mTOR can influence mitochondrial 
function through several molecular pathways: mTORC1 inhibits 
eukaryotic translation initiation factor 4E-binding proteins 
(4EBP) that in turn releases inhibition of eIF4E and promotes 
translation of nuclear-encoded mitochondria-related messenger 
ribonucleic acids  (mRNAs) and an increase in ETC activity 
(57) and mTORC1 positively influences ribosomal protein S6 
kinase beta-1 (S6K1), which negatively regulates mitochondrial 
function through inhibition of the expression of such genes as 
UCP2, PGC1α, and DRP1 (58). Activation of S6K1 by mTORC1 
is inhibited by low-dose rapamycin while high-dose rapamycin 
inhibits both S6K1 and 4EBP (59). Thus, as an additional 
experiment, we examined the effect of mTORC1 by determining 
whether low-dose rapamycin modulates mitochondrial 
respiration and whether such changes are more significant in the 
LCLs with higher respiratory rates (i.e., AD-A LCLs).
METHODS
Lymphoblastoid Cell Lines and Culture 
Conditions
LCLs derived from white males diagnosed with autistic disorder 
(AD) were chosen from pedigrees with at least one other affected 
male sibling (i.e., multiplex family) [mean (SD) age, 8.5 (3.0) 
years]. These LCLs were obtained from the Autism Genetic 
Resource Exchange (Los Angeles, CA, USA) and the National 
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Institute of Mental Health (Bethesda, MD, USA) center for 
collaborative genomic studies on mental disorders. All relevant 
guidelines and regulations were followed. These deidentified 
human samples were determined to be exempt from institutional 
review board (IRB) review by the University of Arkansas for 
Medical Science IRB. Donors were diagnosed using the ADOS or 
the Autism Diagnostic Interview–Revised (ADI-R), both gold-
standard instruments.
In our previous studies (36–42), these LCLs were categorized into 
two different types: ones with atypical mitochondrial respiration 
(AD-A) and those with typical respiration (AD-N). These metabolic 
groupings are repeatable across several studies (36–42). All 
respiratory parameters were reviewed to ensure that the Seahorse 
runs for each LCL were consistent with their assigned group. Only 
one case was found where the Seahorse respiratory measurements of 
an LCL was not consistent with the expected group. One AD-N LCL 
(02C10618) demonstrated baseline respiratory parameters more 
consistent with AD-A LCLs in the rapamycin experiment, so it was 
excluded from the analysis.
CNT LCLs were derived from healthy white boys with no 
documented behavioral or neurological disorder and without any 
first-degree relative suffering from a medical disorder that might 
involve mitochondrial dysfunction [mean (SD) age, 8.5 (2.8) years]. 
CNT LCLs came from Coriell Cell Repository (Camden, NJ, USA).
The average cell passage was 12, with a maximum passage of 15, 
since genomic stability is very high at this low passage number. Cells 
were maintained in Roswell Park Memorial Institute (RPMI) 1640 
culture medium with 15% fetal bovine serum and 1% penicillin/
streptomycin (Invitrogen, Grand Island, NY, USA) in a humidified 
incubator at 37°C with 5% CO2.
Seahorse Assay
A Seahorse Extracellular Flux (XF) 96 Analyzer (Agilent 
Technologies, Santa Clara, CA, USA) measured oxygen 
consumption rate (OCR), an indicator of mitochondrial 
respiration, in live intact LCLs in real time. Each run (each line 
of Supplementary Tables 1 and 2) examined matched LCL 
groups (CNT, AD-N, AD-A) on the same plate to control for 
experimental variation in mitochondrial activity measurement. 
The assay (Figure 1A), which has been described previously 
(36–42), provides measures of ATP-linked respiration (ALR), 
proton leak respiration (PLR), maximal respiratory capacity 
(MRC), and reserve capacity (RC).
Mitochondrial Oxidative Stress Test
To determine the vulnerability of the mitochondria to acute 
ROS exposure, we developed the Mitochondrial Oxidative 
Stress Test (MOST) in our previous studies (43). We examined 
the sensitivity of LCLs to various increasing levels of ROS by 
systematically exposing LCLs to increasing concentrations of 
2,3-dimethoxy-1,4-napthoquinone (DMNQ; Sigma-Aldrich, 
St. Louis, MO, USA) for 1 h prior to the Seahorse assay. LCLs 
were exposed to 0 μM (control no exposure), 5 μM, 10 μM, and 
15 μM DMNQ since these concentrations of DMNQ provide a 
full range of ROS challenge such that the highest concentration 
(15 μM DMNQ) significantly reduced RC to its minimum in 
almost every LCL type. A 5 mg/mL DMNQ solution was diluted 
in DMEM XF assay media into a 10X stock and added to cells in 
an XF-PS plate in a non-CO2 incubator at 37°C 1 h prior to the 
Seahorse assay.
FIGURE 1 | Seahorse assay and outline of the prolonged reactive oxygen species (ROS) exposure experiment. (A) Mitochondrial respiration is inferred by measuring 
oxygen consumption rate (OCR). OCR is measured three times over 18 min at each measurement phase. Initially, basal respiration is measured. The complex V 
inhibitor oligomycin is then used to determine how much of basal respiration is ATP-linked respiration and proton leak respiration. Then, a protonophore, carbonyl 
cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP) is used to drive the respiratory chain to its maximal rate by collapsing the inner membrane gradient, allowing 
maximal respiratory capacity to be determined. To determine non-mitochondrial respiration, antimycin A and rotenone, Complex III and I inhibitors, are added to 
stop the respiratory chain. Reserve capacity is calculated as the difference between basal respiration and maximal respiratory capacity. (B) Prolonged exposure  
(96 h) to a low concentration of DMNQ is used to simulate chronic exposure to a low level of ROS while other cells had no exposure to DMNQ as a control.
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Prolonged Low-Concentration Reactive 
Oxygen Species Exposure
To simulate prolonged exposure to low concentrations of ROS, 
13 sets of LCLs (Supplementary Table 1) were cultured in 1 μM 
DMNQ for 96 h prior to the Seahorse assay or left untreated 
(0 μM) (Figure 1B). Thirteen pairs of AD-N and AD-A LCLs were 
matched with an age-matched male CNT LCL. Due to the low 
availability of CNT LCLs that fit our criteria, a single CNT LCL 
was matched with two ASD LCLs in two cases. Also, three AD-A 
LCLs were matched twice with AD-N LCLs. Matching was 
done to control for variations in measurement of mitochondrial 
function.
Rapamycin Exposure
To determine the influence of the mTOR pathway, we first used 
both low (0.01 nM and 0.1 nM) and high (1 nM and 10 nM) 
concentrations of rapamycin with both 1 h and 2 h exposure 
times on one set of AD-A and AD-N LCLs to determine if there 
was a differential effect of low-dose rapamycin between the 
two cell lines and, if so, the optimal rapamycin concentration 
and exposure time. As a result of this titration, eight pairs of 
AD-A and AD-N LCLs (Supplementary Table 2) were exposed 
to 0.1 nM of rapamycin for 2 h prior to the Seahorse assay or 
left untreated (0 nM). Rapamycin was used as it preferentially 
inhibits the effect of mTORC1 (60), particularly on S6K1 at low 
dose (59).
Gene Expression
Total RNA was isolated from 2 million CNT, AD-N, and 
AD-A LCLs (Supplementary Table 3) using the RNeasy mini 
kit (Qiagen, Hilden, Germany) following the manufacturer’s 
protocol. Complementary deoxyribonucleic acid (cDNA) 
synthesis (2  µg per 20-µL reaction mix) was performed using 
the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Waltham, MA, USA) as indicated by the manufacturer. 
Primers were designed using the online real-time polymerase 
chain reaction (PCR) tool from IDT DNA (www.idtdna.com/
scitools/Applications/RealTimePCR/). Supplementary Table S4 
outlines the primer sequences. Quantitative PCR reactions were 
performed for all target genes using the Power SYBR Green PCR 
Master Mix (Applied Biosystems, Waltham, MA, USA) on an 
ABI 7900HT Fast Real Time PCR system. Relative quantification 
was performed to the housekeeping gene, HPRT1 (hypoxanthine 
phosphoribosyltransferase 1).
Analytic Approach
To analyze group effects, a mixed-model regression was 
conducted via SAS version 9.3 (Cary, NC, USA) “glmmix” 
procedure. The mixed model allows matched samples on each 
Seahorse plate to be compared to one another while controlling 
for any variation associated with the Seahorse assay itself. The 
mitochondrial parameters were response variables with a 
between-group effect of LCL group (e.g., AD-N v AD-A v CNT) 
and within-group repeated factors of prolonged ROS exposure 
(exposed vs. nonexposed) and DMNQ concentration as well 
as the interaction between these effects. DMNQ concentration 
was a continuous variable. For all models, random effects 
included the intercept. F tests evaluated significance. Planned 
post hoc orthogonal contrasts, which are t-distributed, examined 
significant group effects. Data were normally distributed and 
variation was similar across groups. Graphs show standard error 
bars. Gene expression was similarly analyzed, although without 
the DMNQ concentration variable. Rapamycin exposure data 
were similarly analyzed, although the exposure variable was with 
rapamycin. We also performed partial least squares discriminant 
analysis (PLSDA) using R version 3.5.0 mixOmics Omics Data 
Integration Project version 6.3.2.
RESULTS
Prolonged Exposure to Reactive Oxygen 
Species: Mitochondrial Function
To determine if prolonged exposure to low concentrations of 
ROS can alter mitochondrial function, potentially producing 
the atypical patterns of respiration seen in the AD-A LCLs, we 
exposed the three types of LCLs (CNT, AD-N, and AD-A) to 
a low concentration of DMNQ for 96 h or cultured normally 
(control). We then conducted the Seahorse assay including the 
MOST. This allowed us to determine if prolonged ROS exposure 
changed overall average respiration and/or the susceptibility 
of the mitochondria to acute ROS increases. Thus, we report 
the change in overall average respiration and the change in 
respiration with ROS challenge (as part of the MOST) as a result 
of prolonged (96 h) exposure to low levels of ROS.
Adenosine Triphosphate–Linked Respiration
Prolonged ROS exposure increased overall ALR [F(1,1144) = 
4.71, p < 0.05], with this effect not significantly different across 
LCL groups. The change in ALR with increasing DMNQ was 
changed by prolonged ROS exposure [F(1,1144) = 5.07, p < 
0.01] without this change being significantly different across 
LCL groups (Figure 2A). Thus, prolonged ROS exposure 
changed mitochondrial respiration to have a higher baseline 
ALR and a greater change in ALR. This suggests that indeed 
prolonged ROS exposure shifts ALR toward the mitochondrial 
dysfunction abnormalities typically seen in the AD-A LCLs at 
baseline. Interestingly, these changes seem to be similar across 
LCL types, suggesting that it is a general adaptation of the 
mitochondria.
Proton Leak Respiration
Prolonged ROS exposure did influence overall PLR [F(1,1144) = 
52.02, p < 0.001], but this change was not significantly different 
across LCL groups. The typical increase in PLR that occurs with 
redox challenge was amplified after prolonged ROS exposure 
[F(1,1144) = 3.95, p < 0.01] but this change was not significantly 
different across LCL groups (Figure 2B). Thus, prolonged ROS 
exposure changed mitochondrial respiration to have a greater 
change in PLR. This suggests that indeed prolonged ROS 
exposure shifts PLR toward the mitochondrial abnormalities 
seen in the AD-A LCLs at baseline.
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Maximal Respiratory Capacity
Prolonged ROS exposure increased overall MRC [F(1,1144)  = 
4.97, p < 0.05], with this change not significantly different across 
LCL groups. The change (decrease) in MRC was accentuated 
after prolonged ROS exposure [F(1,1144) = 9.37, p  < 0.0001], 
with this effect not significantly different across LCL groups 
(Figure  2C). Thus, prolonged ROS exposure changed 
mitochondrial respiration to increase overall MRC and cause 
a greater change in MRC. This suggests that indeed prolonged 
ROS exposure shifts MRC toward abnormalities seen in the 
AD-A LCLs at baseline.
Reserve Capacity
Prolonged ROS exposure increased overall RC [F(1,1144) = 7.81, 
p < 0.01], with this effect not significantly different across LCL 
groups. Prolonged ROS exposure also augmented the change 
(decrease) in RC [F(1,1144) = 11.55, p < 0.0001] (Figure 2D), with 
this effect significantly different across LCL groups [F(6,1144) = 
2.37, p < 0.05] (Figure 2E). As can be seen in Figure 2E, the change 
in RC with the acute ROS challenge is greater for the AD groups 
than the CNT group. Thus, prolonged ROS exposure changed 
mitochondrial respiration to have a higher overall RC and greater 
change in RC, with some of these effects more prominent in the 
FIGURE 2 | The effect of prolonged (96 h) ROS exposure on mitochondrial function in lymphobastoid cell lines (LCLs). In these expierments, 2,3-dimethoxy-
1,4-napthoquinone (DMNQ) was used to increase ROS in vitro both during the prolonged incubation and 1 h prior to the mitochondrial measurements in order 
to determine the effect of acute increases in ROS on the LCLs. Prolonged ROS exposure (red) shifted mitochondrial function toward an atypical pattern that has 
been reported in a subset of LCLs derived from children with autistic disorder (AD). This includes increasing (A) ATP-linked respiration, (B) proton leak respiration, 
(C) maximal respiratory capacity, and (D) reserve capacity, along with a greater drop in reserve capacity when challanged with an acute increase in ROS. (E) The 
change in reserve capacity with increasing acute DMNQ concetration was different across the LCL groups, so the difference between the lowest (0 µM) and highest 
(15 µM) DMNQ concentrations is depicted in the bottom graph to demonstrate the interaction.
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ASD LCLs. This suggests that indeed prolonged ROS exposure 
shifts RC toward abnormalities seen in the AD-A LCLs at baseline.
Gene Expression Differences Across 
Lymphoblastoid Cell Line Groups: 
Statistical Differences
To understand differences in molecular pathway regulation 
of mitochondrial and redox homeostasis across LCL groups, 
expression of key genes was examined (Figure 3). Gene 
expression was averaged across ROS exposure since differences 
in gene expression between AD and CNT LCL groups were 
independent of the ROS effect except for one gene.
No Differences
There were no differences in PTEN and AKT1 expression 
between LCL groups.
FIGURE 3 | Gene expression in three different types of lymphobastoid cell lines (LCLs) collapsed across the prolonged (96 h) ROS exposure condition. While LCLs 
derived from individuals with autistic disorder (AD) demonstrated increases in expression in several genes, including UCP2, mTOR, and SOD2, in comparison to controls 
(CNT), most of the elevation in gene expression related to the genes involved in response to physiological stress was seen only one AD LCL group (i.e., AD-N).
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Gene Expression Elevated in Autistic Disorder 
Lymphoblastoid Cell Lines Compared to Control 
Lymphoblastoid Cell Lines
UCP2 expression was significantly different across LCL groups 
[F(2,44) = 19.12, p < 0.0001] due to higher expression in AD-N 
[t(44) = 5.54, p < 0.0001] and AD-A [t(44) = 5.31, p < 0.0001] LCLs 
as compared to CNT LCLs. SOD2 expression was significantly 
different across LCL groups [F(2,44) = 19.78, p < 0.0001] due to 
higher expression in AD-N [t(44) = 6.07, p < 0.0001] and AD-A 
[t(44) = 4.68, p < 0.0001] LCLs as compared to CNT LCLs. 
mTOR expression was significantly different across LCL groups 
[F(2,44) = 26.04, p < 0.0001] due to higher expression in AD-N 
[t(44) = 6.63, p < 0.0001] and AD-A [t(44) = 5.99, p < 0.0001] 
LCLs as compared to CNT LCLs.
Gene Expression Elevated in AD-A Lymphoblastoid 
Cell Lines
AMPK expression was significantly different across LCL groups 
[F(2,44) = 6.53, p < 0.005] due to higher expression in the AD-A 
LCL as compared to CNT LCLs [t(44) = 3.61, p < 0.005].
Gene Expression Elevated in AD-N Lymphoblastoid 
Cell Lines
PINK1 expression was significantly different across LCL groups 
[F(2,44) = 19.78, p < 0.0001] due to higher expression in AD-N 
LCLs as compared to CNT [t(44) = 6.20, p < 0.0001] and 
AD-A [t(44) = 3.89, p < 0.0005] LCLs. HIF1α expression was 
significantly different across LCL groups [F(2,44) = 11.99, p < 
0.0001] due to higher expression in AD-N LCLs as compared to 
CNT [t(44) = 4.71, p < 0.0001] and AD-A [t(44) = 3.42, p = 0.001] 
LCLs. SIRT3 expression was significantly different across LCL 
groups [F(2,44) = 14.08, p < 0.0001] due to higher expression 
in AD-N LCLs as compared to CNT [t(44) = 5.16, p < 0.0001] 
and AD-A [t(44) = 3.56, p < 0.001] LCLs. PCG1α expression 
was significantly different across LCL groups [F(2,44) = 7.42, p = 
0.01] due to higher expression in AD-N LCLs as compared to 
CNT [t(44) = 3.70, p < 0.005] and AD-A [t(44) = 2.73, p < 0.05] 
LCLs. MFN2 expression was significantly different across LCL 
groups [F(2,44) = 10.66, p < 0.0005] due to higher expression 
in AD-N LCLs as compared to CNT [t(44) = 2.60, p = 0.01] and 
AD-A [t(44) = 4.60, p < 0.0001] LCLs. SIRT1 expression was 
significantly different across LCL groups [F(2,44) = 3.58, p < 
0.05] due to higher expression in AD-N LCLs as compared to 
AD-A [t(44) = 2.58, p < 0.05] LCLs. DNM1L was significantly 
different across LCL groups [F(2,44) = 6.18, p < 0.005] due to 
higher expression in AD-N LCLs as compared to CNT [t(44) = 
3.51, p < 0.005] LCLs.
Gene Expression Changes Resulting From 
Prolonged Reactive Oxygen Species Exposure
There was also an LCL group by prolonged ROS exposure 
interaction [F(2,44) = 3.24, p = 0.05] driven by the fact that 
MFN2 (fusion) expression decreased in the AD-N LCLs while it 
increased in the CNT [t(44) = 2.27, p < 0.05] and AD-A [t(44) = 
2.10, p < 0.05] LCLs following prolonged ROS exposure.
Gene Expression Patterns Differentiate 
Lymphoblastoid Cell Line Groups:  
Visual Analysis
To better understand gene expression that differentiates LCL 
groups, particularly LCLs with and without mitochondrial 
dysfunction, the statistical differences found above were 
displayed in a functional diagram representing pathway 
interconnections (Figure 4). This diagram shows that ASD 
FIGURE 4 | Interconnection of the pathways studied, the genes in which we have measured expression and connection to mitochondrial respiration. The colors 
represent the groups that have elevations in the expression of specific genes. Most notable are the two pathways by which mTOR can influence mitochondrial 
function. S6K1 pathway inhibits many of the pathways involved in mitochondrial maintainance and response to stress while the 4E-BP/eIF4E pathway more directly 
can increase mitochondrial function.
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LCLs, both AD-A and AD-N LCLs, demonstrate an increase in 
SOD and UCP2, as would be expected for LCLs under chronic 
oxidative stress, as has been shown for ASD LCLs previously 
in several studies (37, 41, 61). One pattern that differentiates 
AD-A from AD-N is that many genes associated with 
mitochondrial maintenance (DRP1, MFN2) and response to 
physiological stress (PCG1α) are only elevated for AD-N LCLs 
but not AD-A LCLs. This is surprising, as the mitochondria 
with more abnormal respiratory rates would be expected to be 
under greater physiological stress.
For both types of ASD LCLs, mTOR is increased, which 
could represent either the mTORC1 or mTORC2 complex, but 
here we concentrate on mTORC1 because of its interactions 
with other pathways. The S6K1 pathway can be promoted by 
mTORC1. Since S6K1 inhibits many of the pathways involved 
in mitochondrial maintenance and response to stress, an 
increase in S6K1 pathway in the AD-A LCLs could explain why 
expression of many of the genes responsible for mitochondrial 
maintenance and response to stress are not elevated. The effect 
of S6K1 specific to mitochondrial dysfunction in the AD-A 
LCLs will be tested in the rapamycin experiment below. Why 
activation of the S6K1 pathway would be greater in the AD-A 
LCLs than in the AD-N LCLs is not immediately obvious, but 
this may be due to the differences in the dynamics of mTOR 
in the two ASD LCL subsets. Indeed, AMPK elevation appears 
to be specific for AD-A LCLs and would result in a greater 
phosphorylation and inactivation of mTORC1. Higher AMPK 
levels could explain the increase in mTOR expression for 
the AD-A LCLs since greater inactivation of mTORC1 could 
drive greater production of unphosphorylated mTORC1. The 
elevation in mTOR expression in AD-N LCLs could be driven 
by PINK1, but we would expect AKT1 to also be increased 
in expression.
Gene Expression Patterns Differentiate 
Lymphoblastoid Cell Line Groups: 
Discriminant Analysis
To complement the qualitative description of the different 
patterns that differentiate the LCL groups, a machine learning 
technique was used to independently verify patterns unique 
to the LCL groups. Since the expression between many genes 
are interdependent, PLSDA was used to select the key genes 
that differentiate LCL characteristics, specifically whether the 
LCLs came from individuals with ASD or those with typical 
development, and whether or not the mitochondria in the 
LCLs manifested mitochondrial dysfunction. Thus, we used 
PLSDA to extract the most important genes that defined 
these specific characteristics. PLSDA was used as compared 
to other discriminant analysis procedures since it considers 
the relationship between genes as well as their absolute 
expression levels.
Autism vs. Nonautism
Overall accuracy of the canonical discriminant function was 
97% using two components that accounted for 56% and 13% 
of the variance. The most significant component loadings were 
represented by six genes: mTOR, UCP2, PTEN, AKT1, SIRT1, 
and MFN2.
Mitochondrial Dysfunction vs. Normal Mitochondrial 
Function
Overall accuracy of the canonical discriminant function was 
84% using two components that accounted for 51% and 11% 
of the variance. The most significant component loadings were 
represented by six genes: mTOR, UCP2, DRP1, AMPK, SIRT1, 
and MFN2.
Thus, the PLSDA demonstrated that several common genes 
differentiated the bioenergetic and clinical characteristics of 
the cells, specifically mTOR, UCP2, SIRT1, and MFN2. Two 
genes were more specific to the clinical characteristics of 
the patients from which the LCLs were derived, specifically 
PTEN and AKT1, and two genes where more specific for the 
bioenergetic characteristics of the LCLs, specifically AMPK 
and DRP1.
Changes in Mitochondrial Respiration 
With Rapamycin Treatment
In order to determine if modulation of S6K1 could affect 
mitochondrial function, we investigated whether low-dose 
rapamycin did indeed differentiate the two ASD LCL groups. 
First, we did a titration experiment to find the optimal low 
dose of rapamycin and to confirm that low-dose but not high-
dose rapamycin differentially influenced the two ASD groups. 
As seen in Figure 5, low-dose rapamycin markedly reduced 
the respiratory indexes in the AD-A LCLs but not the AD-N 
LCLs as expected. From these experiments, we selected the 
optimal low dose to examine this effect on a larger number of 
LCL pairs.
Mitochondrial function was measured in eight pairs of 
LCLs from the two AD LCL groups (AD-N and AD-A) with 
and without exposure to low-dose (0.1 nM) rapamycin since 
this concentration of rapamycin has a more selective effect 
on the regulation of S6K1 by mTOR (59). We hypothesized 
that the activation of S6K1 by mTORC1 suppresses genes 
for  mitochondrial maintenance and response to stress and 
that by decreasing activity of this pathway using low-dose 
rapamycin, mitochondrial dysfunction in the AD-A LCLs will 
normalize.
Analyzing the results by LCL group, rapamycin was found to 
decrease PLR [F(1,13) = 7.37, p < 0.05] but not ALR (Figure 6A 
and B). Consistent with our hypothesis, rapamycin significantly 
decreased MRC [F(1,13) = 20.06, p < 0.001] and RC [F(1,13) = 
23.41, p < 0.001], with this effect significantly greater for the 
AD-A LCLs [MRC: F(1,13) = 12.07, p < 0.005; RC: F(1,13) = 
23.05, p < 0.001] as compared to the AD-N LCLs (Figure 6C 
and D). In fact, for AD-A LCLs, MRC and RC decreased toward 
the AD-N respiratory parameters indicating normalization to 
these respiratory parameters.
We then determined if the effect of low-dose rapamycin was 
dependent on baseline mitochondrial respiration independent 
of the LCL grouping, by examining the relationship between 
the baseline respiratory parameters and the change in the 
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respiratory parameter with rapamycin exposure. A significant 
relationship between the baseline respiratory parameter and 
change in the respiratory parameter with rapamycin treatment 
was found for all respiratory parameters [ALR: F(1,12) = 7.85, 
p < 0.05, r = −0.71; PLR: F(1,12) = 14.35, p < 0.005, r = −0.63; 
MRC: F(1,12) = 8.20, p = 0.01, r = −0.69; RC: F(1,12) = 12.77, 
p < 0.005, r = −0.74; Figure 6E–H]. In general, rapamycin had 
a greater effect on reducing mitochondrial respiration for those 
LCLs with higher respiratory rates at baseline. All correlation 
coefficients were significant, and these relationships were not 
significantly different across AD groups. Thus, in general, 
it appeared that rapamycin had a greater effect on reducing 
mitochondrial respiration when mitochondrial respiratory rates 
were higher.
DISCUSSION
This study examines important aspects of mitochondrial function 
and the origins of atypical mitochondrial respiration previously 
observed in a subset of ASD LCL in at least seven independent 
studies (36–42). In our previous studies, we hypothesized that 
FIGURE 5 | The effect of both low-dose and high-dose rapamycin on one pair of ASD LCLs. LCLs were exposed to low dose (0.01 nM and 0.1 nM) or high dose 
(1 nM and 10 nM) for either 1 h or 2 h followed by the Seahorse assay. For presentation purposes, both low doses at both time points were combined into one 
average data point and both high doses at both time points were combined into one data point. Standard error bars are also shown. Respiratory parameters 
including (A) ATP Linked Respiration, (B) Maximal Respiratory Capacity and (C) Reserve Capacity are shown.
FIGURE 6 | Rapamycin modulates mitochondrial function differently depending on the underlying baseline repiratory rate in lymphobastoid cell lines (LCLs) derived 
from children with autistic disorder (AD). (A–D) Group differences in the effect of rapamycin. The AD-N LCLs demonstrate more typical mitochondrial function and 
have less influence from rapamycin while the AD-A LCLs, which demonstrate elevated mitochondrial function, are more influenced by rapamycin. (E–H) The linear 
relationship between the underlying baseline respiratory rate and the change in respirataory rate for both groups of LCLs. The higher the baseline respiratory rate, 
the greater the effect of rapamycin.
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ASD LCLs with atypical mitochondrial respiration, called 
AD-A LCLs, developed atypical mitochondrial respiration as 
an adaptation to previous environmental exposures, potentially 
through prolonged exposure to ROS since oxidative stress is a 
common mechanism in which environmental agents perturb 
cellular physiology.
In this study, we conducted three experiments: 1) we 
examined the effect of prolonged exposure to ROS on 
mitochondrial respiration; 2) we examined differences in the 
expression of genes important for mitochondrial respiration, 
particularly those involved in allowing the mitochondria to 
adapt to adverse physiological conditions, across different 
clinical types (ASD vs. typical developing) and physiological 
types (atypical vs. normal mitochondrial function); and 
3) we also examined the effect of low-dose rapamycin on 
mitochondrial function, to determine whether a specific 
regulatory pathway (S6K1) may be involved in maintaining 
atypical mitochondrial function in the AD-A LCLs.
First, we examined the effect of prolonged exposure to 
low concentrations of an agent (DMNQ) that increased 
intracellular ROS to alter baseline mitochondrial respiration. 
We examined this in three types of LCLs, those derived 
from typically developing children (CNT) and two types from 
children with ASD. One of the subsets of LCLs derived from 
children with ASD are known to have atypical mitochondrial 
respiration (AD-A), which has been hypothesized to be an 
adaptive response to previous exposures to environmental 
stressors involving ROS. The prolonged exposure to ROS 
did result in changes in mitochondrial respiration, some of 
which were more significant and marked in the AD LCLs, but, 
overall, did influence the CNT LCLs also. These changes were 
similar to the differences seen in the AD-A LCLs at baseline, 
suggesting that the pattern of mitochondrial dysfunction 
displayed in the AD-A LCLs may have arisen from previous 
prolonged exposure to ROS.
Interestingly, the analysis of changes in gene expression with 
prolonged exposure to ROS found that MFN2 (fusion) gene 
expression changed, although in different directions for the 
different LCLs groups. While MFN2 expression decreased for 
AD-N LCLs and increased for both AD-A and CNT LCLs, it needs 
to be noted that the AD-N LCLs showed a higher expression 
of this gene at baseline. What is also potentially significant is 
that MFN2 appears to be significant in differentiating both 
clinical groups and bioenergetic characteristics of the LCLs, 
pointing to the potential importance of the maintenance of 
optimal mitochondria function in ASD. It is also of interest 
that the AD-A LCLs demonstrated significantly lower MFN2 
at baseline as compared to the AD-N LCLs. Thus, in lowering 
MFN2 expression for AD-N LCLs, prolonged ROS exposure 
did alter MFN2 toward the baseline expression of the AD-A 
LCLs, suggesting that this difference in MFN2 expression may 
be an integral part of the regulation and maintenance of the 
atypical mitochondrial activity.
Second, we examined gene expression in three types of 
LCLs that have different intrinsic mitochondrial function 
and underlying intracellular ROS profiles. Both types of ASD 
LCLs demonstrated increased expression of UCP2, SOD2, 
and mTOR. As both types of ASD LCLs are known to have 
increased intracellular ROS, it is not surprising that UCP2 and 
SOD2 were increased, although our previous study suggested 
that UCP2 was higher in AD-A as compared to AD-N LCL 
when the protein content was measured (37). Further, since 
glutathionylation (62) activates UCP2, relative changes in 
glutathione in the ASD LCLs also likely modulate UCP2 
function. Thus, UCP2 gene expression between ASD LCLs only 
provides one aspect of its function in LCLs under chronic ROS.
The AD-N LCLs clearly demonstrated an increase in 
several genes involved in mitochondrial response to stress and 
mitochondrial dynamics aimed at improving mitochondrial 
fidelity. Previous studies have demonstrated that overexpression 
of PCG1α in ASD LCLs results in upregulation of mitochondrial 
ETC Complex I and III as well as reduces mitochondrial 
ROS (54). Thus, AD-N LCLs appear to have pathways for 
supporting mitochondrial response to stress even without an 
exogenous ROS challenge. The fact that the AD-A LCLs did 
not demonstrate an increase in these genes was surprising 
and may suggest that their abnormal mitochondrial function 
is an alternative adaptation to the chronic intracellular ROS. 
Visual analysis of pathways suggested that the S6K1 pathway, 
which is activated by mTORC1, could suppress these pathways 
and account for a suppression of pathways important for 
mitochondrial response to stress and maintenance. Our third 
experiment tests this hypothesis.
The AD-A LCLs also demonstrated an increase in AMPK 
expression, which is unexpected as AMPK is inhibited by 
elevation in intracellular ATP, and from our previous studies, 
the AD-A appears to be overproducing ATP. This result would 
appear to suggest that despite increased production of ATP, 
AD-A LCLs remain at an overall ATP deficit or, alternatively, an 
upstream signal is activating AMPK. Either way, this elevation 
in AMPK can significantly affect mTORC1 levels in the LCLs as 
higher AMPK will enhance the phosphorylation of mTORC1, 
thereby inactivating its influences on downstream signals. This 
could explain the increase in mTOR expression for the AD-A 
LCLs as more mTOR would need to be produced to maintain an 
active mTORC1 complex.
Third, we examined the effect of low-dose rapamycin on 
parameters of mitochondrial respiration. We found that overall 
rapamycin decreased MRC and RC, with this decrease much 
greater in the LCLs with higher respiration, the AD-A LCLs, 
as compared to those with lower respiratory rates, the AD-N 
LCLs. We also found that the effect of low-dose rapamycin 
in decreasing respiratory parameters was proportional to the 
amount they were increased at baseline, so that the higher 
the baseline respiratory parameter value, the more low-
dose rapamycin decreased the parameter. This appears to be 
consistent across the four respiratory parameters measured. 
Others have found that low-dose rapamycin modulates the 
effect of mTOR on S6K1. S6K1 inhibits several of the genes 
that are elevated in the AD-N but not the AD-A LCLs. Thus, 
by decreasing the positive influence of mTOR on S6K1, the 
inhibitory effect on genes associated with mitochondrial 
response to stress and mitochondria maintenance could be 
uninhibited. If these mitochondrial regulatory pathways were 
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responsible for maintaining normal mitochondrial respiration 
in the context of chronic oxidative stress, uninhibiting 
them could normalize mitochondrial function in the AD-A 
LCLs. This is exactly what was found. However, the effect of 
normalizing mitochondrial respiration was proportional to the 
abnormal elevation in mitochondrial respiration regardless of 
whether the LCLs were in the AD-A or AD-N group. Thus, 
this does suggest that the abnormalities in mitochondrial 
respiration may be on a continuum. Such a notion would be 
consistent with the fact that chronic exposure to ROS can 
change the respiratory characteristics of LCLs toward this 
atypical pattern with the magnitude of this change different for 
the different LCL groups.
mTORC1 is known to stimulate mitochondrial ATP 
production (57, 63), but both ASD LCLs demonstrate similar 
mTOR gene expression. The AD-A LCLs demonstrate 
elevated expression of AMPK that phosphorylates regulatory-
associated protein of mTOR (RAPTOR), inhibiting its activity. 
This would be expected to decrease the activity of the mTOR 
pathway. However, the rapamycin experiments suggest that 
the mTOR pathway is relevant to mitochondrial function 
in AD-A LCLs. It is possible that the increased sensitivity 
to rapamycin and the preferential activation of the S6K1 
pathways as compared to the 4E-BP pathway by mTORC1 in 
AD-A LCLs are due to the fact that it has a more narrow range 
of activation because it is chronically inhibited by a chronic 
increase in AMPK.
The Role of Mitochondrial Dysfunction 
in Neurodevelopmental Disorders
Interestingly, the pattern of a significant elevation in 
mitochondrial respiratory activity found in the AD-A LCLs 
is not unprecedented and has been associated with genetic 
syndromes and models of ASD resulting from environmental 
influences. For example, genetic syndromes associated with 
ASD, including patients with Phelan–McDermid syndrome 
(33), WDR45 (17), 22q13 duplication (21), and Rett syndrome 
(18), as well as the PTEN haploinsufficient mouse model of 
ASD (16) have demonstrated significant elevations in ETC 
function. Also, brain tissue from the maternal immune 
activation (MIA) mouse, a model of ASD induced by prenatal 
environmental stress, has overactivity in Complex I and 
IV (64). This abnormal pattern of mitochondrial function 
has also been associated with other disorders. For example, 
ETC Complex IV underactivity is found in chronic multiple 
sclerosis lesions during inflammation but ETC Complex 
IV has been found to be overactive in these lesions once 
inflammation has resolved, suggesting that inflammation 
had a long-term effect on mitochondrial activity (65, 66). 
Significantly, this “hyperactive” state of ETC Complex IV has 
been described during reperfusion following ischemia and 
is believed to contribute to the increased production of ROS 
during reperfusion (67). Thus, a better understanding of this 
atypical increase in respiratory rate and its role in disease may 
have significant consequences.
The Link Between Environmental Factors 
and Mitochondrial Function
Interestingly, consistent with the chronic ROS exposure 
experiment, we have found that environmental influences 
associated with ASD can alter mitochondrial function in CNT 
LCLs to make them more like AD-A LCLs, thereby supporting 
our original hypothesis. For example, in a recent study, we 
demonstrated that prolonged exposure to trichloroacetaldehyde 
hydrate, the active metabolite of an environmental toxicant 
associated with ASD, can alter CNT LCLs to have mitochondrial 
function like AD-A LCLs and that AD-A LCLs are more resilient 
to the detrimental effect of trichloroacetaldehyde hydrate on 
the mitochondria as compared to AD-N LCLs (40). In addition, 
further studies have implicated the enteric microbiome-derived 
short-chain fatty acids butyrate (42) and propionic acid (39) 
in increasing respiratory rates of mitochondria in LCLs from 
children with ASD.
Overall, we believe that the experiments reported in this 
manuscript may provide insight into adaptive changes in 
mitochondrial function that are only starting to be recognized. 
We believe that these changes may be caused by environmental 
influences in many cases and the information uncovered may be 
helpful in understanding environmentally induced diseases in 
greater depth. In addition, it appears that the mTOR pathway may 
have a role in modulating changes in mitochondrial function in 
the context of these atypical changes in mitochondrial function 
and may have a role in developing novel treatments.
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